Abstract: The present invention relates to a novel use of .beta.-receptor blocking agents for preparation of a drug for treatment of Meniere's disease.
Abstract: The present invention relates to compositions and methods for inhibiting protein aging. Accordingly, a composition is disclosed which comprises an agent or compound capable of inhibiting the formation of advanced glycosylation end products of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. Suitable agents may contain an active nitrogen-containing group, such as a hydrazine group. Particular agents comprise aminoguanidine, .alpha.-hydrazinohistidine and mixtures thereof. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.
Type:
Grant
Filed:
February 20, 1990
Date of Patent:
July 7, 1992
Assignee:
The Rockefeller University
Inventors:
Anthony Cerami, Peter C. Ulrich, Michael Brownlee
Abstract: This invention relates to the use of tenidap, presently shown as the enolic form of 5-chloro-2,3-dihydro-2-oxo-3-(2-thienylcarbonyl)-indole-1-carboxamide, and the pharmaceutically-acceptable base salts thereof to reduce total serum cholesterol, LDL cholesterol and triglycerides in a mammal having an inflammatory arthritic condition. The methods of this invention comprise administering an effective amount of tenidap or salts thereof to a mammal.
Abstract: The present invention relates to a method of lowering plasma triglycerides in a patient in need thereof comprising administering to said patient an effective hypotriglyceridemic amount of a bis(3,5-di-alkyl-4-hydroxyphenylthio)methane.
Type:
Grant
Filed:
June 19, 1990
Date of Patent:
June 16, 1992
Assignee:
Merrell Dow Pharmaceuticals Inc.
Inventors:
Simon J. T. Mao, George Ku, Richard L. Jackson
Abstract: The use of a compound of the formula (I): ##STR1## wherein R is hydroxy or 2-methoxyethylamino or a pharmaceutically acceptable salt thereof, in lowering triglyceride and/or cholesterol levels and/or increasing high density lipoprotein levels. These compounds may be used in treating hypertriglycerdaemia, hypercholesterolaemia, conditions of low HDL (high density lipoprotein) levels and atherosclerotic disease.
Type:
Grant
Filed:
November 14, 1990
Date of Patent:
June 9, 1992
Assignee:
Imperial Chemical Industries PLC
Inventors:
Brian R. Holloway, Jacqueline M. Jackson
Abstract: The present invention is a method for lowering serum levels of Lp(a), thereby reducing the risk of atherosclerotic disease. Specifically, the present invention comprises administering an effective amount of a N,S-diacyl-L-cysteine to a human or animal with elevated serum levels of Lp(a). The N,S-diacyl-L-cysteines comprise a compound selected from the group having the formula: ##STR1## wherein R is selected from the group consisting of hydrogen and an alkyl group containing 1 to 8 carbon atoms and R' is selected from the group consisting of acetyl, benzoly, thenoyl, 2-chromone-carbonyl and succinyl, and pharmaceutically acceptable salts thereof.
Type:
Grant
Filed:
March 13, 1991
Date of Patent:
May 19, 1992
Assignee:
Medicis Corporation
Inventors:
John W. Holaday, Jonah Shacknai, Leonard L. Mazur
Abstract: Pharmaceutical preparations are provided for preventing or treating autoimmune diseases in which the active principle is activated T-lymphocyte cells, specific for the autoimmune disease to be treated, which cells have been treated by incubation with a photoactivatable psoralen cross-linking agent, such as 8-methoxypsoralen, and then photoactivated. The active principle may also be the membrane fraction of such cells. Such preparations may be formulated into pharmaceutical compositions and administered to prevent or treat autoimmune disesases.
Type:
Grant
Filed:
March 15, 1989
Date of Patent:
May 19, 1992
Assignee:
Yeda Research and Development Co. Ltd.
Inventors:
Irun R. Cohen, Meir Shinitzky, Richard L. Edelson
Abstract: A parenteral formulation comprising abouta) 0.01-0.4% by weight of nimodipine, relative to 100 parts by weight of a solvent comprising aboutb)30-70% by weight of water15-40% by weight of propylene glycol and/or polyethylene glycol, and15-30% by weight of ethanoland, where appropriate, customary auxiliaries and/or additives.
Abstract: A method of treating cardiac arrhythmias and muscle tension and spasticity with N-(1-methyl-3-pyrrolidinyl)-1-(phenylmethyl)-1H-benzimidazol-2-amine and analogs and the pharmaceutical compositions are herein disclosed. Illustratively, the compound having the structure: ##STR1## corrects an induced arrhythmia in 7 out of 8 dogs at 7 mg/kg IV and has an ED.sub.50 of 21 mg/kg in the mouse Straub-tail test.
Abstract: The present invention relates to a group of compounds which are novel squalene derivatives containing the cyclopropyloxy functionality and which act to inhibit the synthesis of cholesterol in mammals and in fungi.
Type:
Grant
Filed:
June 28, 1991
Date of Patent:
April 7, 1992
Assignee:
Merrell Dow Pharmaceuticals Inc.
Inventors:
Michael R. Angelastro, Norton P. Peet, Philippe Bey
Abstract: There are disclosed a process for producing an .alpha.-acyloxy-.alpha.,.beta.-unsaturated carbonyl compound represented by the general formula (VI): ##STR1## wherein R.sub.1, R.sub.2 and R.sub.4 are independently hydrogen atoms or substituted or unsubstituted hydrocarbon residues, or R.sub.1 and R.sub.2, when taken together with one another in an optional combination, form a ring, R.sub.3 is a substituted or unsubstituted hydrocarbon residue, and indicates that the configuration may be either E-configuration or Z-configuration, in particular, a 20-acyloxy-17(20)-methylen-21-al-steroid represented by the partial structural formula (II): ##STR2## wherein R is a hydrocarbon residue, and indicates that the configuration of the acyloxy group and the formyl group bonded to the carbon atom at the 20-position may be either E-configuration or Z-configuration, which comprises oxidizing a propargyl ester represented by the general formula (V): ##STR3## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.
Abstract: Pharmaceutical compositions and their preparation which contain dihydrolipoic acid or its pharmaceutically acceptable salts as active substance. The pharmaceutical compositions have a cytoprotective effect and are suitable for combatting pain and inflammatory disorders.
Type:
Grant
Filed:
February 8, 1990
Date of Patent:
January 28, 1992
Assignee:
Asta Pharma Aktiengesellschaft
Inventors:
Heinz Ulrich, Carl-Heinrich Weischer, Jurgen Engel, Helmut Hettche
Abstract: The present invention is novel compounds which are 1,2,4-triazoles, derivatives of fenamates and pharmaceutically acceptable additions and base salts thereof, pharmaceutical compositions and methods of use therefor. The nvention compounds are now found to have activity as inhibitors of 5-lipoxygenase and/or cyclooxygenase providing treatment of conditions advantageously affected by such inhibition including inflammation, arthritis, pain, fever, and the like.
Type:
Grant
Filed:
April 3, 1990
Date of Patent:
November 19, 1991
Assignee:
Warner-Lambert Co.
Inventors:
Diane H. Boschelli, David T. Connor, Daniel L. Flynn, Jagadish C. Sircar, Milton L. Hoefle
Abstract: Novel 7.beta.-hydroxy-4-pregnene-3,20-dione derivatives are disclosed.The group of these compounds has possibility of being utilized as an intermediate for the synthesis of progesterone derivatives having ovulation-inhibiting activity. These compounds themselves have also cell differentiation activity for M1 cells.
Type:
Grant
Filed:
September 26, 1988
Date of Patent:
July 2, 1991
Assignee:
Snow Brand Milk Products Co., Ltd.
Inventors:
Makoto Yoshihama, Koji Tamura, Nobuo Miyata, Masamichi Nakakoshi
Abstract: A composition capable of preserving moisture-containing agriculture products succeptible to mold spoilage from mold spoilage for an extended period of time comprising a mold-inhibiting agent, a quaternary ammonium compound, and a polyglycol and the method of preserving agricultural products utilizing the composition.
Abstract: A one phase, liquid composition for oral administration comprises a NSAID such as an indoleacetic acid derivative or a pyrroleacetic acid derivative plus a di- or triglyceride of a medium chain fatty acid edible oil which has the characteristics of a pharmaceutical solvent carrier as known to those skilled in the art. Other pharmaceutical additives may be optionally added. An additional stipulation is that ethanol or other monohydric alcohol solvents should not be present.
Abstract: Contraceptive methods and delivery systems involving few undesirable side effects during administration are based on novel triphasic estrogen/progestogen combinations, wherein the amount of estrogen is increased stepwise over the three phases.